605 related articles for article (PubMed ID: 3129926)
1. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
2. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
Kopelman HA; Woosley RL; Lee JT; Roden DM; Echt DS
Am J Cardiol; 1988 May; 61(13):1006-11. PubMed ID: 3284316
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Kus T; Campa MA; Nadeau R; Dubuc M; Kaltenbrunner W; Shenasa M
Am Heart J; 1992 Jan; 123(1):82-9. PubMed ID: 1729853
[TBL] [Abstract][Full Text] [Related]
5. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
Hoffmann E; Mattke S; Haberl R; Steinbeck G
J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686
[TBL] [Abstract][Full Text] [Related]
6. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction.
Koch KT; Düren DR; van Zwieten PA
Cardiovasc Drugs Ther; 1995 Jun; 9(3):437-43. PubMed ID: 8527354
[TBL] [Abstract][Full Text] [Related]
7. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
Nademanee K; Singh BN
Am J Cardiol; 1990 Jan; 65(2):53A-57A; discussion 65A-66A. PubMed ID: 2403735
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
Steinbeck G; Bach P; Haberl R
J Am Coll Cardiol; 1986 Oct; 8(4):949-58. PubMed ID: 3760368
[TBL] [Abstract][Full Text] [Related]
10. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
Kus T; Costi P; Dubuc M; Shenasa M
Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
[TBL] [Abstract][Full Text] [Related]
11. The antiarrhythmic effects of d-sotalol.
Schwartz J; Crocker K; Wynn J; Somberg JC
Am Heart J; 1987 Sep; 114(3):539-44. PubMed ID: 3630894
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
Kehoe RF; MacNeil DJ; Zheutlin TA; Ezri MD; Nazari J; Spangenberg RB; Dunnington C; Lueken M
Am J Cardiol; 1993 Aug; 72(4):56A-66A. PubMed ID: 8346728
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
[TBL] [Abstract][Full Text] [Related]
14. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest.
Singh SN; Cohen A; Chen YW; Wish M; Thoben-O'Grady L; Peralba J; Gottdiener J; Fletcher RD
Am J Cardiol; 1988 Sep; 62(7):399-402. PubMed ID: 2458026
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.
Kühlkamp V; Mermi J; Mewis C; Braun U; Seipel L
Eur Heart J; 1995 Nov; 16(11):1625-31. PubMed ID: 8881857
[TBL] [Abstract][Full Text] [Related]
16. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
17. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
Antz M; Cappato R; Kuck KH
J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Kuchar DL; Garan H; Venditti FJ; Finkelstein D; Rottman JN; McComb J; McGovern BA; Ruskin JN
Am J Cardiol; 1989 Jul; 64(1):33-6. PubMed ID: 2741811
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
[TBL] [Abstract][Full Text] [Related]
20. Recurrent sustained ventricular tachycardia 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens.
Horowitz LN; Josephson ME; Farshidi A; Spielman SR; Michelson EL; Greenspan AM
Circulation; 1978 Dec; 58(6):986-97. PubMed ID: 709782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
